一种改良的克里斯滕森尿素和CLSI肉汤微量稀释法，用于检测六种马拉色菌属菌种对伏立康唑、伊曲康唑和酮康唑的敏感性。
A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.
作者信息
Rincón S, Cepero de García M C, Espinel-Ingroff A
机构信息
Centro De Investigactiones Microbiológicas CIMIC, Universidad de los Andes, Bogotá, Columbia.
出版信息
J Clin Microbiol. 2006 Sep;44(9):3429-31. doi: 10.1128/JCM.00989-06.
Abstract
Two supplemented broths (Christensen's urea with 0.1% Tween 80 and 0.5% Tween 40 and RPMI 1640 with 1% glycerol, 1% peptone, 1.8% glucose, and 0.05% Tween 80) were evaluated to determine voriconazole, itraconazole, and ketoconazole MICs for 200 Malassezia sp. isolates. Malassezia globosa and M. restricta were the least susceptible species (MICs at which 90% of the isolates tested were inhibited, 1 to >or=8 microg/ml versus 0.25 to 1 microg/ml).
摘要
评估了两种补充肉汤（含0.1%吐温80和0.5%吐温40的克里斯滕森尿素肉汤以及含1%甘油、1%蛋白胨、1.8%葡萄糖和0.05%吐温80的RPMI 1640培养基），以确定200株马拉色菌属分离株对伏立康唑、伊曲康唑和酮康唑的最低抑菌浓度（MIC）。球形马拉色菌和限制性马拉色菌是最不易感的菌种（90%受试分离株被抑制时的MIC值分别为1至≥8μg/ml对比0.25至1μg/ml）。
相似文献
1
A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.
J Clin Microbiol. 2006 Sep;44(9):3429-31. doi: 10.1128/JCM.00989-06.
2
Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest.
J Clin Microbiol. 2004 Aug;42(8):3589-93. doi: 10.1128/JCM.42.8.3589-3593.2004.
3
Antifungal activities of azole agents against the Malassezia species.
Int J Antimicrob Agents. 2007 Mar;29(3):281-4. doi: 10.1016/j.ijantimicag.2006.09.016. Epub 2007 Jan 16.
4
Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and Malassezia globosa to azole drugs and amphotericin B evaluated using a broth microdilution method.
Med Mycol. 2014 Aug;52(6):641-6. doi: 10.1093/mmy/myu010. Epub 2014 Jun 25.
5
Assessment of the antifungal susceptibility of Malassezia pachydermatis in various media using a CLSI protocol.
Vet Microbiol. 2012 Oct 12;159(3-4):536-40. doi: 10.1016/j.vetmic.2012.04.034. Epub 2012 May 2.
6
In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.
Antimicrob Agents Chemother. 2003 Jul;47(7):2342-4. doi: 10.1128/AAC.47.7.2342-2344.2003.
7
In vitro antifungal susceptibility of Malassezia pachydermatis from dogs with and without skin lesions.
Vet Microbiol. 2012 Mar 23;155(2-4):395-8. doi: 10.1016/j.vetmic.2011.09.008. Epub 2011 Sep 12.
8
Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Chemotherapy. 2007;53(4):300-5. doi: 10.1159/000102585. Epub 2007 May 10.
9
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
J Clin Microbiol. 2001 Mar;39(3):954-8. doi: 10.1128/JCM.39.3.954-958.2001.
10
[In vitro antifungal activity of azoles and amphotericin B against Malassezia furfur by the CLSI M27-A3 microdilution and Etest methods].
Rev Iberoam Micol. 2017 Apr-Jun;34(2):89-93. doi: 10.1016/j.riam.2016.05.004. Epub 2017 Feb 14.
引用本文的文献
1
Antifungal properties of carvone and linalool against species: Preliminary Screening Study.
Curr Med Mycol. 2024 Nov 25;10. doi: 10.22034/cmm.2024.345248.1547. eCollection 2024.
2
A novel urease gene structure of Sporosarcina pasteurii with double operons.
Mol Genet Genomics. 2025 Feb 22;300(1):25. doi: 10.1007/s00438-025-02236-8.
3
In Vitro Assessment of Azole and Amphotericin B Susceptibilities of spp. Isolated from Healthy and Lesioned Skin.
J Fungi (Basel). 2022 Sep 13;8(9):959. doi: 10.3390/jof8090959.
4
: Zoonotic Implications, Parallels and Differences in Colonization and Disease in Humans and Animals.
J Fungi (Basel). 2022 Jul 4;8(7):708. doi: 10.3390/jof8070708.
5
Antifungal Resistance among Less Prevalent Non- and Other Yeasts versus Established and under Development Agents: A Literature Review.
J Fungi (Basel). 2021 Jan 4;7(1):24. doi: 10.3390/jof7010024.
6
In Vitro Azole and Amphotericin B Susceptibilities of from Bloodstream Infections Using E-Test and CLSI Broth Microdilution Methods.
Antibiotics (Basel). 2020 Jun 26;9(6):361. doi: 10.3390/antibiotics9060361.
7
A Ketoconazole Susceptibility Test for Using Modified Leeming⁻Notman Agar.
J Fungi (Basel). 2018 Nov 16;4(4):126. doi: 10.3390/jof4040126.
8
Methodological Issues in Antifungal Susceptibility Testing of Malassezia pachydermatis.
J Fungi (Basel). 2017 Jul 5;3(3):37. doi: 10.3390/jof3030037.
9
Agar Diffusion Procedures for Susceptibility Testing of Malassezia pachydermatis: Evaluation of Mueller-Hinton Agar Plus 2 % Glucose and 0.5 µg/ml Methylene Blue as the Test Medium.
Mycopathologia. 2015 Oct;180(3-4):153-8. doi: 10.1007/s11046-015-9913-2. Epub 2015 Jul 3.
10
Prolonged fever and splenic lesions caused by Malassezia restricta in an immunocompromised patient.
Pediatr Transplant. 2014 Dec;18(8):E283-6. doi: 10.1111/petr.12351. Epub 2014 Sep 3.
本文引用的文献
1
Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species.
J Clin Microbiol. 2005 Jun;43(6):2824-9. doi: 10.1128/JCM.43.6.2824-2829.2005.
2
Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest.
J Clin Microbiol. 2004 Aug;42(8):3589-93. doi: 10.1128/JCM.42.8.3589-3593.2004.
3
In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.
Antimicrob Agents Chemother. 2003 Jul;47(7):2342-4. doi: 10.1128/AAC.47.7.2342-2344.2003.
4
Identification of Malassezia species from patient skin scales by PCR-RFLP.
Clin Microbiol Infect. 2002 Mar;8(3):162-73. doi: 10.1046/j.1469-0691.2002.00383.x.
5
Malassezia species in skin diseases.
Curr Opin Infect Dis. 2002 Apr;15(2):133-42. doi: 10.1097/00001432-200204000-00006.
6
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
Mycopathologia. 2001;150(3):101-15. doi: 10.1023/a:1010954803886.
7
Susceptibility testing of Malassezia species using the urea broth microdilution method.
Antimicrob Agents Chemother. 2000 Aug;44(8):2185-6. doi: 10.1128/AAC.44.8.2185-2186.2000.
8
In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine.
Br J Dermatol. 2000 Apr;142(4):758-65. doi: 10.1046/j.1365-2133.2000.03294.x.
9
In vitro activities of ketoconazole, econazole, miconazole, and Melaleuca alternifolia (tea tree) oil against Malassezia species.
Antimicrob Agents Chemother. 2000 Feb;44(2):467-9. doi: 10.1128/AAC.44.2.467-469.2000.
10
Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo.
Infection. 1997 Sep-Oct;25(5):303-6. doi: 10.1007/BF01720401.
Zotero 插件